Neoplasms

Skin and Connective Tissue Diseases

All Conditions

Digestive System Diseases

Respiratory Tract (Lung and Bronchial) Diseases

Gland and Hormone Related Diseases

Blood and Lymph Conditions

Immune System Diseases

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Symptoms and General Pathology

Infections

Rare Diseases

Breast Neoplasms

Stomach Neoplasms

Carcinoma

Carcinoma, Squamous Cell

Lung Neoplasms

Small Cell Lung Carcinoma

Carcinoma, Hepatocellular

Pancreatic Neoplasms

Lymphoma

Uterine Cervical Neoplasms

Melanoma

Carcinoma, Renal Cell

Head and Neck Neoplasms

Microsatellite Instability

Carcinoma, Transitional Cell

Carcinoma, Merkel Cell

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Neuroendocrine Tumors

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Germ Cell and Embryonal

Neoplasms, Nerve Tissue

Adenocarcinoma

Urogenital Neoplasms

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Kidney Neoplasms

Urologic Neoplasms

Kidney Diseases

Urologic Diseases

Male Urogenital Diseases

Carcinoma, Bronchogenic

Bronchial Neoplasms

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Endocrine Gland Neoplasms

Pancreatic Diseases

Endocrine System Diseases

Communicable Diseases

Polyomavirus Infections

Virus Diseases

DNA Virus Infections

Tumor Virus Infections

Carcinoma, Neuroendocrine

Genomic Instability

Stomach Cancer

Small Cell Lung Cancer

Pancreatic Cancer

Lymphosarcoma

Renal Cell Carcinoma

Clear Cell Renal Cell Carcinoma

Transitional Cell Carcinoma

Merkel Cell Carcinoma

Neuroendocrine Tumor

Neuroepithelioma

All Drugs and Chemicals

Dermatologic Agents

Immunomodulating Agents

Coal Tar

Long Term follow-up of subjects who have received an allogeneic, iPSC-derived NK cell in a previous trial.

No study drug is administered in this study. Subjects who received an allogeneic, iPSC-derived NK cell in a previous trial will be evaluated in this trial for long-term safety and efficacy

Allogeneic natural killer (NK) cell

Fate Trial Disclosure

Subjects who previously took part in the FT500-101 study and received allogeneic NK cell immunotherapy will take part in this long term follow-up study. Subjects will automatically enroll into study FT-003 once they have withdrawn or complete the parent interventional study.

The purpose of this study is to provide long-term safety and survival data for subjects who have participated in the parent study. No additional study drug will be given, but subjects can receive other therapies for their cancer while they are being followed for long term safety in this study.

This is a multicenter, non-interventional, observation study designed to provide long-term safety and efficacy data on subjects who have participated in a prior Fate Therapeutics interventional study of FT500 cellular immunotherapy. Subjects will be contacted every six months (± one month), beginning six months after subject completion or withdrawal from the FT500-101 study.

Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy

OS defined as the interval between the date of the first NK cell infusion and the date of death due to any cause

Fate Therapeutics

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy	NCT04106167	Advanced Solid ... Lymphoma Gastric Cancer Colorectal Canc... Head and Neck C... Squamous Cell C... EGFR Positive S... HER2-positive B... Hepatocellular ... Small-cell Lung... Renal Cell Carc... Pancreas Cancer Melanoma NSCLC Urothelial Carc... Cervical Cancer Microsatellite ... Merkel Cell Car...	Allogeneic natu...	18 Years -	Fate Therapeutics
Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy	NCT04106167	Advanced Solid ... Lymphoma Gastric Cancer Colorectal Canc... Head and Neck C... Squamous Cell C... EGFR Positive S... HER2-positive B... Hepatocellular ... Small-cell Lung... Renal Cell Carc... Pancreas Cancer Melanoma NSCLC Urothelial Carc... Cervical Cancer Microsatellite ... Merkel Cell Car...	Allogeneic natu...	18 Years -	Fate Therapeutics
Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy	NCT04106167	Advanced Solid ... Lymphoma Gastric Cancer Colorectal Canc... Head and Neck C... Squamous Cell C... EGFR Positive S... HER2-positive B... Hepatocellular ... Small-cell Lung... Renal Cell Carc... Pancreas Cancer Melanoma NSCLC Urothelial Carc... Cervical Cancer Microsatellite ... Merkel Cell Car...	Allogeneic natu...	18 Years -	Fate Therapeutics

Spots Global Cancer Trial Database for allogeneic natural killer (nk) cell